The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma
Myeloma NCCN guidelines remain relevant and current, adding new regimens with promising early-phase data, and removing regimens that become obsolete over time. However, this process is inconsistent and may benefit from standardization.
Authors
- Vinay Prasad (ORCID: https://orcid.org/0000-0002-6110-8221)
- Jehad Almasri (ORCID: https://orcid.org/0000-0001-6098-8450)
- Ghulam Rehman Mohyuddin (ORCID: https://orcid.org/0000-0001-6464-783X)
- Alyson Haslam (ORCID: https://orcid.org/0000-0002-7876-3978)
- Aaron M. Goodman (ORCID: https://orcid.org/0000-0002-6196-9427)
Institutions
- University of California, San Francisco (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- University of California San Diego (US)
- University of Cincinnati (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1093/oncolo/oyae332
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00